SAAL1 and hepatocellular carcinoma: In our study, we found that inhibition of SAAL1 expression significantly impaired the HGF/Met-driven PI3K/Akt/mTOR signaling pathway, and depletion of SAAL1 can restore chemosensitivity of HCC cells towards both sorafenib and foretinib treatment.